SE9900495D0 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
SE9900495D0
SE9900495D0 SE9900495A SE9900495A SE9900495D0 SE 9900495 D0 SE9900495 D0 SE 9900495D0 SE 9900495 A SE9900495 A SE 9900495A SE 9900495 A SE9900495 A SE 9900495A SE 9900495 D0 SE9900495 D0 SE 9900495D0
Authority
SE
Sweden
Prior art keywords
sub
vaccine composition
monoglyceride
killed
tuberculosis
Prior art date
Application number
SE9900495A
Other languages
English (en)
Swedish (sv)
Inventor
Ulf Scroeder
Stefan Svenson
Original Assignee
Pharmatrix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatrix Ab filed Critical Pharmatrix Ab
Priority to SE9900495A priority Critical patent/SE9900495D0/xx
Publication of SE9900495D0 publication Critical patent/SE9900495D0/xx
Priority to AU28035/00A priority patent/AU769390B2/en
Priority to PCT/EP2000/001046 priority patent/WO2000047225A2/en
Priority to NZ513130A priority patent/NZ513130A/xx
Priority to US09/926,001 priority patent/US6936260B1/en
Priority to DE60031243T priority patent/DE60031243T2/de
Priority to EP00906305A priority patent/EP1154792B1/en
Priority to AT00906305T priority patent/ATE342065T1/de
Priority to ES00906305T priority patent/ES2275495T3/es
Priority to DK00906305T priority patent/DK1154792T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9900495A 1999-02-12 1999-02-12 Vaccine composition SE9900495D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition
AU28035/00A AU769390B2 (en) 1999-02-12 2000-02-09 Vaccine composition
PCT/EP2000/001046 WO2000047225A2 (en) 1999-02-12 2000-02-09 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
NZ513130A NZ513130A (en) 1999-02-12 2000-02-09 Vaccine composition containing a monoglyceride adjuvant with inactivated Mycobacterium tuberculosis bacteria
US09/926,001 US6936260B1 (en) 1999-02-12 2000-02-09 Vaccine composition
DE60031243T DE60031243T2 (de) 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
EP00906305A EP1154792B1 (en) 1999-02-12 2000-02-09 Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
AT00906305T ATE342065T1 (de) 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
ES00906305T ES2275495T3 (es) 1999-02-12 2000-02-09 Formulacion de la vacuna contra la tuberculosis que contiene como adyuvante monogliceridos o acidos grasos.
DK00906305T DK1154792T3 (da) 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition

Publications (1)

Publication Number Publication Date
SE9900495D0 true SE9900495D0 (sv) 1999-02-12

Family

ID=20414469

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition

Country Status (10)

Country Link
US (1) US6936260B1 (da)
EP (1) EP1154792B1 (da)
AT (1) ATE342065T1 (da)
AU (1) AU769390B2 (da)
DE (1) DE60031243T2 (da)
DK (1) DK1154792T3 (da)
ES (1) ES2275495T3 (da)
NZ (1) NZ513130A (da)
SE (1) SE9900495D0 (da)
WO (1) WO2000047225A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
AU2002364952B2 (en) * 2001-11-14 2008-04-10 Novavax, Inc. Mycobacterial vaccine
ATE466585T1 (de) * 2001-12-11 2010-05-15 Pasteur Institut Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
CU23476A1 (es) * 2004-01-29 2009-12-17 Ct Ingenieria Genetica Biotech Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
WO2006079989A2 (en) * 2005-01-28 2006-08-03 North-West University Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
JP5713672B2 (ja) * 2007-04-12 2015-05-07 ジェニファー ライター， 結核のワクチンおよびその使用方法
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
CA2833633A1 (en) * 2011-04-20 2012-10-26 Jason Fisher Composition and method for enhancing an immune response
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
WO2018006939A1 (en) 2016-07-05 2018-01-11 Universidad De Zaragoza Inactivated tuberculosis vaccine
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (en) * 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
DE69735294T2 (de) * 1996-03-25 2006-09-21 Medarex Inc. Spezifische monoklonale antikörper für die extrazelluläre domäne von protasta-spezifischem membranantigen
SE9602280D0 (sv) * 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering

Also Published As

Publication number Publication date
DK1154792T3 (da) 2007-02-12
WO2000047225A3 (en) 2000-12-14
DE60031243T2 (de) 2007-05-24
US6936260B1 (en) 2005-08-30
WO2000047225A2 (en) 2000-08-17
ES2275495T3 (es) 2007-06-16
AU769390B2 (en) 2004-01-22
EP1154792A2 (en) 2001-11-21
EP1154792B1 (en) 2006-10-11
DE60031243D1 (de) 2006-11-23
AU2803500A (en) 2000-08-29
ATE342065T1 (de) 2006-11-15
NZ513130A (en) 2003-01-31

Similar Documents

Publication Publication Date Title
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
DE122010000040I1 (de) Solubilisierung von capsulären Polysacchariden
CY1106206T1 (el) Φαρμακευτικη συνθεση πepιεχουσα φενοφιβρατη και μεθοδος παρασκευης της
NO20002741D0 (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
NZ513202A (en) Antigen composition comprising Bordetella bronchiseptica, formalin and glutaraldehyde
ATE195740T1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
MXPA04000680A (es) Vacuna para virus west nile.
ATE342065T1 (de) Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
DE60202379D1 (de) Neuartige verbindungen
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
PT792165E (pt) Composicoes imunogenicas
NZ333226A (en) Immunstimulating lipid formulation
EP1395283A4 (en) HETEROLOGICAL PROTECTION, INDUCED BY IMMUNIZATION WITH THE INVAPLEX VACCINE
SE9900496D0 (sv) Vaccine formulation
HK1046404A1 (zh) 用作nmda受体拮抗剂的取代的吡咯烷-2，3，4-三酮-3-肟衍生物
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
EP2364726A3 (en) Vaccine against neisseria infection
PL365334A1 (en) Use of zinc derivatives as cyclic ester polymerisation catalysts
SE9402241L (sv) Inhibitor
SE0100011D0 (sv) Virus vaccine formulation